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Background: Vascular endothelial dysfunction is involved in macrovascular disease progression in type 2 diabetes
mellitus (T2DM). We reported previously that blood glucose fluctuations, as evaluated by continuous glucose
monitoring (CGM), correlate with vascular endothelial function, serving as a marker of vascular endothelial function.
However, the use of CGM is limited, suggesting the need for another marker of vascular endothelial function. Here, we
investigated the relationship between vascular endothelial dysfunction and blood levels of 1,5-anhydro-D-glucitol
(1,5-AG), a marker of both postprandial hyperglycemia and fluctuations in blood glucose.
Methods: In 32 inpatients with T2DM and HbA1c less than 8.0%, the reactive hyperemia index (RHI), an index of
vascular endothelial function, was determined by peripheral arterial tonometry. The relationships between RHI and
1,5-AG, blood glucose, lipid metabolism markers, and blood pressure, were examined.
Results: There was a strong correlation between 1,5-AG and natural logarithmic-scaled RHI (L_RHI) (r = 0.55; P = 0.001).
However, there was no correlation between L_RHI and HbA1c, fasting blood glucose, IRI, LDL-C, HDL-C, TG, systolic
blood pressure, or diastolic blood pressure. Multivariate analysis identified blood 1,5-AG levels to be the only significant
and independent determinant of L_RHI.
Conclusions: In T2DM with HbA1c <8.0%, low 1,5-AG levels were associated with vascular endothelial dysfunction,
suggesting it is a potentially useful marker for vascular endothelial dysfunction.
Trial registration: UMIN000015317
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Atherosclerosis causes vascular endothelial dysfunction
even at an early stage [1], and is known to play a major
role in the development and progression of macrovascular
disease in type 2 diabetes mellitus (T2DM) [2]. A study
using the blood glucose clamp technique showed that
endothelial dysfunction progresses via increased oxidative
stress associated with fluctuations in blood glucose level
[3]. Studies from our laboratory have also reported that
the standard deviation (SD) and the mean amplitude of
glycemic excursions (MAGE), i.e., indices of fluctuations
in blood glucose as determined by continuous glucose* Correspondence: tanaka@med.uoeh-u.ac.jp
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unless otherwise stated.monitoring (CGM), correlate significantly with vascular
endothelial function [4]. It has become apparent that
evaluation of blood glucose fluctuations by CGM is useful
for predicting vascular endothelial function. However, the
number of patients who use CGM is limited. We also re-
ported previously that hemoglobin A1c (HbA1c) cannot
predict vascular endothelial function [4]. Accordingly, we
explored the utility of other markers of glycemic control
that are evaluated in daily clinical practice as predictors of
vascular endothelial function.
The level of 1,5-anhydro-D-glucitol (1,5-AG) in periph-
eral blood is considered a useful marker of glycemic con-
trol [5,6] and a useful predictor of cardiovascular events
[7]. The present study was designed to determine the rela-
tionship between vascular endothelial function and blood
levels of 1,5-AG in patients with T2DM.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The present cross-sectional study included 32 patients
with T2DM admitted to the University of Occupational
and Environmental Health Hospital and Wakamatsu
Hospital of the University of Occupational and Environ-
mental Health between January 2012 and November 2013.
All patients satisfied the following inclusion criteria: (1) age
20 years and above; (2) HbA1c <8.0%; (3) serum creatinine
(Cre) <2.0 mg/dl; and (4) the absence of arrhythmias. Pa-
tients with diabetic ketoacidosis, nonketotic hyperosmolar
coma, infection, or acute coronary syndrome were excluded
from the study. The study protocol was approved by the
Human Ethics Review Committee and a signed consent
form was obtained from each subject.
Study design
This study was a cross-sectional study. On the second or
third hospital day, fasting blood plasma glucose (FPG) was
measured, together with HbA1c, 1,5-AG, immunoreactive
insulin (IRI), low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), and trigly-
ceride (TG). Vascular endothelial function was assessed
noninvasively using peripheral arterial tonometry (PAT)
apparatus (EndoPAT2000, Itamar Medical, Caesarea,
Israel) [8]. The reactive hyperemia index (RHI), which is a
vasodilatory response to the release of avascularization and
reflects the ability to produce nitric oxide (NO) in vivo
stimulated by vascular shear stress, was measured automat-
ically by PAT [9]. Evaluation of vascular endothelial func-
tion with EndoPAT includes the use of the contralateral
arm as the control side, and RHI is calculated automatic-
ally. This evaluation technique is reported to involve less
examiner-dependent variation and to be superior in terms
of objectivity compared to the FMD evaluation [10]. No
changes were made in oral glucose-lowering agents, lipid
metabolism-improving drugs, or antihypertensive drugs
from 12 weeks before admission until the end of the study.
The primary endpoint of the study was the relationship
between RHI and 1,5-AG, while the secondary endpoints of
the study were the relationships between RHI and HbA1c,
IRI, homeostasis model of assessment insulin resistance
(HOMA-IR), lipid metabolism, and blood pressure.
Noninvasive vascular function test
The method used for endothelial function measurement
using PAT has been described in detail previously [11].
Briefly, after an overnight fast, the subject rested in a
temperature- and light-controlled room for a period of
30 min. Baseline pulse amplitude was recorded during a
period of 5 min prior to the induction of ischemia. The lat-
ter was induced by placing the blood pressure cuff on the
upper arm. The opposite arm served as a control. The PAT
probes were placed on index finger of each hand. After
5 min, the blood pressure cuff was inflated to 200 mmHgor 60 mmHg above the systolic pressure if systolic pressure
was over 140 mmHg for 5 min and then deflated to induce
reactive hyperemia. As a measure of reactive hyperemia,
RHI was calculated as the ratio of the average amplitude of
the PAT signal over 1 min beginning 1.5 min after cuff de-
flation (control arm, A; occluded arm, C) divided by the
average amplitude of the PAT signal over the 2.5-min time
period before cuff inflation (baseline) (control arm, B; oc-
cluded arm, D). Thus, RHI = (C/D)/(A/B) x baseline cor-
rection. Because RHI has a heteroscedastic error structure,
we used a natural logarithm transformation in all analyses.Measurement of serum lipids, blood HbA1c, 1,5-AG and
plasma glucose
Serum lipids were measured using a Hitachi 7350 autoana-
lyzer (Hitachi Co., Tokyo, Japan). LDL-C, HDL-C, and TG
were determined by the enzymatic method, and LDL-C
was determined by the direct method. HOMA-IR was
calculated using the following formula: HOMA-IR = [fast-
ing IRI (μU/l) × fasting blood glucose (mg/dl)/405]. HbA1c
(%) was measured by HPLC using Tosoh HLC-723 G8
(Tosoh Co., Kyoto, Japan), and expressed as National
Glycohemoglobin Standardization Program (NGSP) values
by adding 0.4% to HbA1c values expressed as the conven-
tional Japanese standard substance (JDS) values [12]. The
1,5-AG level was measured by a colorimetric method
(Nippon Kayaku, Tokyo, Japan) using a Bio Majesty JCA-
BM 8060 (JEOL, Tokyo, Japan).Statistical analyses
All values were expressed as mean ± SD. The Kolmogorov-
Smirnov normality test demonstrated that natural
logarithmic-scaled RHI (L_RHI), 1,5-AG, HbA1c, FPG,
LDL-C, TG, systolic blood pressure (SBP), and diastolic
blood pressure (DBP) were normally distributed, whereas
IRI and HOMA-IR showed skewed distribution. For inter-
group comparisons, the unpaired t-test was used for nor-
mally distributed data, the Mann–Whitney U test for data
with skewed distributions. To assess potential correlations
with L_RHI, the Pearson correlation coefficient was used
for data with normal distribution pattern, whereas the
Spearman rank-correlation coefficient was used for data
with a non-normal distribution. Multivariate analysis was
carried out employing the step-up procedure, using L_RHI
as the dependent variable, and age, sex, body mass index
(BMI), disease duration, use of presence/absence of treat-
ment with α-glucosidase inhibitor treatment or insulin
treatment, use of antihypertensive drugs, use of antihyper-
lipidemic drugs, history of cardiovascular disease (CVD),
LDL-C, HDL-C, TG, SBP, DBP, HbA1c, 1,5-AG, and FPG
as independent variables. The level of significance was set
at p < 0.05. SPSS Statistical Software 21.0 (SPSS Inc., Chi-
cago, IL) was used for all statistical analyses.
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Clinical characteristics
Table 1 lists the clinical features of the 32 (17 men and 15
women) participating patients. The mean L_RHI value
was 0.6 ± 0.2 (men: 0.6, women: 0.7) (range: 0.3-1.0), and
the mean baseline pulse amplitude was 8.5 ± 4.0 (men: 8.7,
women: 8.3), with neither value showing any significant
difference between the sexes.
Relationship between L_RHI and markers of diabetes
control and nonglycemic metabolic variables
The relationship between L_RHI and clinical markers of
glycemic control is shown in Table 2. Univariate analysis
showed a statistically significant relationship between
L_RHI and 1,5-AG (r = 0.55; P = 0.001). On the other
hand, L_RHI did not correlate with HbA1c, FPG, IRI, orTable 1 Patient characteristics
Age (years) 64.0 ± 11.1 [37–79]
Gender (male/female) 17/15
Body mass index (kg/m2) 26.0 ± 5.3
Duration of diabetes (years) 11.3 ± 12.8 [1–45]
Diabetes therapy




α-glucosidase inhibitor 3 (9.0)
Dipeptidyl peptidase-4 inhibitor 7 (22.0)
Insulin 5 (15.6)
Other treatments
Lipid-lowering drugs 13 (41.0)
Antihypertensive drugs 14 (44.0)
Current smokers 8 (25.0)
Prevalence cardiovascular disease 7 (22.0)
Systolic blood pressure (mmHg) 135.1 ± 20.0
Diastolic blood pressure (mmHg) 78.3 ± 12.5
LDL-cholesterol (mg/dl) 121.3 ± 23.8
HDL-cholesterol (mg/dl) 50.5 ± 16.9
Triglyceride (mg/dl) 119.8 ± 60.1
HbA1c (%) 7.3 ± 0.5 [6.2-7.9]
1,5-anhydro-D-glucitol (μg/ml) 7.4 ± 3.5 [2.6-15.3]
Fasting plasma glucose (mg/dl) 128.1 ± 25.3 [75–185]
Immunoreactive insulin (μU/ml)a 8.4 ± 8.6
HOMA-IRa 2.6 ± 2.4
L_RHI 0.6 ± 0.2
Data are mean ± SD [range], n, or (%). an = 27.
LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin
A1c; HOMA-IR, homeostasis model assessment as an index of insulin resistance;
L_RHI, the natural logarithmic scaled reactive hyperemia index.HOMA-IR. L_RHI also did not correlate with LDL-C,
HDL-C, TG, SBP, or DBP.
In the next step, we compared the relationship between
L_RHI and treatment with and without sulfonylurea, pio-
glitazone, metformin, α-glucosidase inhibitor, dipeptidyl
peptidase-4 inhibitor, and insulin. There was no relation-
ship between L_RHI and treatment with and without sulfo-
nylurea (0.64 ± 0.09 vs 0.61 ± 0.04, p = 0.818), pioglitazone
(0.71 ± 0.13 vs 0.60 ± 0.04, p = 0.311), metformin (0.77 ±
0.09 vs 0.58 ± 0.04, p = 0.060), and dipeptidyl peptidase-4
inhibitor treatment (0.72 ± 0.11 vs 0.59 ± 0.04, p = 0.210).
On the other hand, L_RHI was significantly higher in the
α-glucosidase inhibitor-treated group (0.86 ± 0.04, n = 3)
than -untreated group (0.59 ± 0.04, n = 29) (P = 0.042), and
significantly lower in the insulin-treated group (0.38 ± 0.04,
n = 5) than -untreated group (0.66 ± 0.04, n = 27) (P = 0.006).
Multivariate analysis, using L_RHI as the dependent
variable and age, sex, BMI, disease duration, use of pres-
ence/absence of treatment with α-glucosidase inhibitor
treatment or insulin treatment, use of antihypertensive
drugs, use of antihyperlipidemic drugs, history of CVD,
LDL-C, HDL-C, TG, SBP, DBP, HbA1c, 1,5-AG, and FPG
as the independent variables, identified 1,5-AG as the only
significant and independent determinant of L_RHI (ad-
justed multiple R2 = 0.277, standardization coefficient β =
0.548, t = 3.149, P = 0.001) (Table 3).
Because the incidence of cardiovascular events is report-
edly increased significantly in patients with L_RHI of ≤0.4
[13], the subjects were divided into two groups; the low
L_RHI group (L_RHI ≤0.4, n = 7) and the high L_RHI
group (L_RHI >0.4, n = 25). The 1,5-AG level was statisti-
cally significantly lower in the low L_RHI group (4.7 ±
1.8 μg/ml) compared with high L_RHI group (8.1 ±
3.6 μg/ml) (p = 0.023). However, HbA1c was not statisti-
cally significantly different between the two groups (low
group:7.3 ± 0.3%, high group:7.2 ± 0.5%, p = 0.855).
Discussion
The main finding of the present study was that vascular
endothelial function parameter L_RHI correlates signifi-
cantly with 1,5-AG in T2DM patients with HbA1c <8.0%.
In fact, 1,5-AG blood level correlate with postprandial
hyperglycemia in patients with HbA1c <8.0%, in both type
1 diabetes mellitus [14] and T2DM [15]. In addition, the
use of CGM has demonstrated a significant correlation
with MAGE and indices of postprandial hyperglycmia
in patients with HbA1c <8.0% [16]. 1,5-AG has been clinic-
ally used as a marker of changes in blood glucose level.
Sakamoto et al. [17] used this parameter to compare
changes in blood glucose level according to glucose-
lowering therapy, similar to CGM data. Furthermore, since
low 1,5-AG levels are associated with coronary artery
disease, 1,5-AG has also been used to identify patients
at high risk of cardiovascular disease [18]. Furthermore,
Table 2 Correlation coefficients between L_RHI and clinical markers of glycemia and various nonglycemic metabolic
variables
HbA1c 1,5-AG FPG IRI HOMA-IR LDL-C HDL-C TG SBP DBP
1,5-AG (n = 32) −0.38*
FPG (n = 32) 0.18 −0.24
IRI (n = 27) 0.26 0.19 −0.15
HOMA-IR (n = 27) 0.27 0.17 −0.02 0.98**
LDL-C (n = 32) −0.02 −0.28 −0.17 −0.03 −0.04
HDL-C (n = 32) −0.14 −0.06 0.07 −0.43* −0.45* −0.40*
TG (n = 32) −0.01 −0.04 −0.17 0.27 0.20 0.28 −0.70**
SBP (n = 32) −0.11 −0.05 −0.39* 0.11 0.06 0.34 −0.08 −0.01
DBP (n = 32) −0.09 −0.13 −0.14 0.32 0.27 0.18 −0.06 −0.01 0.72**
L_RHI (n = 32) −0.08 0.55** −0.25 0.14 0.06 0.08 −0.04 0.01 0.03 −0.19
Data are results of Pearson correlation analysis for normally distributed variables and Spearman rank correlation for variables with skewed distribution.
*P < 0.05, **P < 0.01.
Abbreviations as in Table 1. 1,5-AG, 1,5-anhydro-D-glucitol; FPG, Fasting plasma glucose; IRI, Immunoreactive insulin; HDL-C, high-density lipoprotein cholesterol;
TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Torimoto et al. Cardiovascular Diabetology 2014, 13:99 Page 4 of 6
http://www.cardiab.com/content/13/1/99blood 1,5-AG levels correlated inversely with serum Cre
levels especially in patients with Cre ≥2.0 mg/dl [15]. Based
on the reported relationship between 1,5-AG blood levels
and HbA1c <8.0% and Cre <2.0 mg/dl described above
[14,15], we focused in this study on patients with HbA1c
<8.0%.
Blood 1,5-AG level is a marker of glycemic control
and accurately reflects rises and falls in urinary glucose
excretion. When 1,5-AG leaks into the urine along with
excessive excretion of glucose, the result is a decreased
concentration in the blood. In other words, blood glu-
cose levels correlate inversely with those of 1,5-AG [19].
Because glucose is immediately excreted into the urine
even after a very short period of postprandial hypergly-
cemia, 1,5-AG was previously reported to serve as a
marker of glycemic control that reflects fluctuations in
blood glucose [20-22]. On the other hand, in relation to
complications, 1,5-AG reportedly correlates with albu-
minuria [23] and the cardio-ankle vascular index [24],
independent of HbA1c. A cohort study that followed
subjects for a mean of 11 years demonstrated 1,5-AG to
be a strong predictor of CVD [7]. Emoto et al. [25] re-
ported that improvement in flow mediated dilation dur-





Adjusted Multiple R2 0.277
Multivariate stepwise regression analysis with L_RHI as the dependent variable and
treatment with α-glucosidase inhibitor treatment or insulin treatment, antihyperten
cholesterol, triglyceride, systolic blood pressure, HbA1c, 1,5-AG, and fasting plasma
Abbreviations as in Tables 1 and 2: SE, Standard error; CVD, cardiovascular disease;associated with 1,5-AG improvement in patients with
type 2 diabetes accompanied by coronary artery disease.
However, there is only limited information on 1,5-AG
and vascular endothelial function, and no study free of
the effects of drug treatments has yet been reported. In
the present study, vascular endothelial function, evalu-
ated by PAT, correlated strongly with 1,5-AG, suggesting
the 1,5-AG level is a potentially useful predictor of vascu-
lar endothelial function, as well as a marker of fluctuations
in blood glucose, in patients with HbA1c <8%. Based on
this result, we believe that 1,5-AG should be evaluated in
patients with HbA1c <8%, and that treatment of postpran-
dial hyperglycemia and multidisciplinary risk management
for atherosclerosis should be provided to patients with low
1,5-AG levels.
L_RHI is mainly an index of vascular endothelial func-
tion that reflects vasodilatory responses to NO, an
endothelium-dependent vasodilatory factor [26]. Vascular
endothelial function determined by L_RHI is reported to
allow detection of atherosclerosis at an early stage and to
correlate with coronary atherosclerosis [11], as well as to
predict coronary artery disease [13]. As for the relation-
ship between glucose metabolism and vascular endothelial







0.548 3.149 0.001 0.015-0.053
age, gender, BMI, duration of the disease, use of presence/absence of
sive drugs, lipid-lowering drugs, prevalence CVD, LDL-cholesterol, HDL-
glucose as the independent variables.
95% CI, 95% confidence interval.
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endothelial dysfunction [3], and indices of fluctuations in
blood glucose, such as MAGE and postprandial hypergly-
cemia, correlate strongly with vascular endothelial func-
tion [4]. Specifically, fluctuations in blood glucose and
postprandial hyperglycemia are considered to be major
factors favoring the progression of vascular endothelial
dysfunction in glucose metabolism. On the other hand, it
was recently reported that 1,5-AG correlates with MAGE
and postprandial hyperglycemia in CGM [16,27]. The
findings of this study indicate that 1,5-AG correlates
strongly with vascular endothelial function because it is a
marker of glycemic control that reflects, particularly fluc-
tuations in blood glucose and postprandial hyperglycemia.
This study has several limitations. First, this study did
not include control subjects free of diabetes mellitus.
Second, we did not evaluate the relationship between vas-
cular endothelial function with either oxidative stress or in-
flammation. Third, about half of the subjects were on
treatment intended to improve lipid metabolism. Although
a relationship between L_RHI and blood pressure or the ra-
tio of TC to HDL-C was found in a large-scale cohort study
[28], no relationship was found between L_RHI and blood
pressure or lipid metabolism in our study, presumably be-
cause most of our patients were on antihypertensive drugs
or statins. Fourth, the determination coefficient of the inde-
pendent variable was low for the model employed in this
study, with the adjusted R2 being equal to 0.277 in multi-
variate analysis. The sample size was relatively small, and
therefore the obtained results require further confirmation
in a larger number of patients.
Conclusions
The present study demonstrated that low levels of 1,5-AG,
a marker of fluctuations in blood glucose level, are associ-
ated with vascular endothelial dysfunction in patients with
HbA1c <8.0%.Abbreviations
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